Takeda goes all in on China — Aims to capture $170B market slice

Eric Oliver - Print  |

Takeda has a new "core country" in its sights: China, Bloomberg reports.

Here's what you should know:

1. Takeda is readying to launch seven new drugs in China in the next five years, more than it has planned for any other region.

2. Takeda CEO Christophe Weber is confident Takeda's Shire acquisition will earn Chinese government approval, despite concerns the government could delay issuing its approval in retaliation to recently passed U.S. tariffs.

3. He said, "There's no reason in the long- term China shouldn't be our second-biggest business in the world." Mr. Weber said Takeda is planning to launch drugs in the country at the same tempo as its other core markets.

4. To help accomplish this aim, Takeda securing reimbursement from China's insurance program.

5. Takeda's reasons for targeting China are clear. China's pharmaceutical market is second to the U.S. in size, with expenditures predicted to grow to $170 billion by 2021, according to the QuintilesIMS.

More articles on gastroenterology:
6 strategies for improving anesthesia patient handoffs
Penn Highlands Healthcare project to add 400 new jobs, includes ASC : 3 insights
Little Rock Diagnostic Clinic considering sale to CHI St. Vincent — 3 insight

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.